| 1A. Paolo Fundarò | | | 1B. Jerome Durso | | | 1C. Srinivas Akkaraju, M.D., Ph.D. | | | ||
| 1D. Luca Benatti, Ph.D. | | | 1E. Daniel Bradbury | | | 1F. Keith Gottesdiener, M.D. | | | ||
| 1G. Nancy Miller-Rich | | | 1H. Mark Pruzanski, M.D. | | | 1I. Dagmar Rosa-Bjorkeson | | | ||
| 1J. Gino Santini | | | 1K. Glenn Sblendorio | | | | | | | |
| | | Page | | |||
| | | | 1 | | | |
| | | | 1 | | | |
| | | | 6 | | | |
| | | | 9 | | | |
| | | | 9 | | | |
| | | | 14 | | | |
| | | | 15 | | | |
| | | | 15 | | | |
| | | | 15 | | | |
| | | | 16 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | 19 | | | |
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | |
| | | Page | | |||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | ||
| | | | | | |
Director | | Age | | Director Since | | | Age | | Director Since | | ||||||||||||||||
Paolo Fundarò(1) | | | | 48 | | | | | 2006 | | | | | | 49 | | | | | 2006 | | | ||||
Jerome Durso | | | | 54 | | | | | 2021 | | | | | | 55 | | | | | 2021 | | | ||||
Srinivas Akkaraju, M.D., Ph.D.(6) | | | | 54 | | | | | 2012 | | | | | | 55 | | | | | 2012 | | | ||||
Luca Benatti, Ph.D.(5)(6) | | | | 61 | | | | | 2014 | | | | | | 62 | | | | | 2014 | | | ||||
Daniel Bradbury(3)(5) | | | | 60 | | | | | 2016 | | | | | | 61 | | | | | 2016 | | | ||||
Keith Gottesdiener, M.D.(6) | | | | 68 | | | | | 2016 | | | | | | 69 | | | | | 2016 | | | ||||
Nancy Miller-Rich(4)(5) | | | | 63 | | | | | 2018 | | | | | | 64 | | | | | 2018 | | | ||||
Mark Pruzanski, M.D.(6) | | | | 54 | | | | | 2002 | | | | | | 55 | | | | | 2002 | | | ||||
Dagmar Rosa-Bjorkeson(4) | | | | 58 | | | | | 2021 | | | | | | 59 | | | | | 2021 | | | ||||
Gino Santini(2)(3)(4) | | | | 65 | | | | | 2015 | | | | | | 66 | | | | | 2015 | | | ||||
Glenn Sblendorio(3) | | | | 66 | | | | | 2014 | | | | | | 67 | | | | | 2014 | | |
| | | Number of shares subject to awards (thousands) | | | Weighted average exercise price ($) | | | Weighted average remaining contractual term (years) | | |||||||||
Outstanding stock options | | | | | 2,554 | | | | | | 38.72 | | | | | | 7.4 | | |
Expected to vest | | | | | 1,285 | | | | | | 19.82 | | | | | | 8.9 | | |
Exercisable | | | | | 1,269 | | | | | | 57.86 | | | | | | 5.9 | | |
Outstanding RSUs (excluding PSUs) | | | | | 1,536 | | | | | | | | | | | | | | |
Outstanding PSUs (at 100% vesting) | | | | | 512 | | | | | | | | | | | | | | |
Outstanding PSUs (at 150% vesting) | | | | | 768 | | | | | | | | | | | | | | |
Outstanding RSUs (including PSUs at 100%) | | | | | 2,048 | | | | | | | | | | | | | | |
Outstanding RSUs (including PSUs at 150%) | | | | | 2,304 | | | | | | | | | | | | | | |
Shares available for grant (PSUs at 100%) | | | | | 2,791 | | | | | | | | | | | | | | |
Shares available for grant (PSUs at 150%) | | | | | 2,535 | | | | | | | | | | | | | | |
Fiscal period | | | Options granted | | | RSUs granted | | | PSUs granted (at 100%) | | | PSUs granted (at 150%) | | | RSUs + PSUs granted (at 100%) | | | RSUs + PSUs granted (at 150%) | | | PSUs earned | | |||||||||||||||||||||
Q1 2023* | | | | | 517 | | | | | | 849 | | | | | | 225 | | | | | | 337 | | | | | | 1,074 | | | | | | 1,186 | | | | | | 0 | | |
2022 | | | | | 543 | | | | | | 711 | | | | | | 169 | | | | | | 253 | | | | | | 880 | | | | | | 964 | | | | | | 0 | | |
2021 | | | | | 1,305** | | | | | | 830 | | | | | | 177 | | | | | | 265 | | | | | | 1,007 | | | | | | 1,095 | | | | | | 0 | | |
2020 | | | | | 727 | | | | | | 660 | | | | | | 65 | | | | | | 97 | | | | | | 725 | | | | | | 757 | | | | | | 0 | | |
| | | Life Science | | | Leadership & Management | | | U.S. Public Company Boards | | | Research & Development | | | Sales & Commercial | | | Business Development | | | Operations | | | Finance & Banking | | ||||||||||||||||||||||||
Paolo Fundarò | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | | | | | | | | | | | | | ✓ | | | | | | | | | | | | ✓ | | |
Jerome Durso | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | |
Srinivas Akkaraju, M.D., Ph.D. | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | ✓ | | | | | | | | | | | | ✓ | | |
Luca Benatti, Ph.D. | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | ✓ | | | | | | | | | | | | | | | | | | ✓ | | | | | | | | |
Daniel Bradbury | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | |
Keith Gottesdiener, M.D. | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | | | | | | | ✓ | | | | | | | | |
Nancy Miller-Rich | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | | | |
Mark Pruzanski, M.D. | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | | | | | | | ✓ | | | | | | | | |
Dagmar Rosa-Bjorkeson | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | |
Gino Santini | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | |
Glenn Sblendorio | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | | | | | | | | | | | | | | | | | ✓ | | | | | | ✓ | | | | | | ✓ | | |
Board Diversity Matrix (As of April 1, 2022) | | ||||||||||||
Total Number of Directors | | | 11 | | |||||||||
| | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | |
Part I: Gender Identity | | | | | | | | | | | | | |
Directors | | | 2 | | | 8 | | | — | | | 1 | |
Part II: Demographic Background | | | | | | | | | | | | | |
African American or Black | | | — | | | — | | | — | | | — | |
Alaskan Native or Native American | | | — | | | — | | | — | | | — | |
Asian | | | — | | | 1 | | | — | | | — | |
Hispanic or Latinx | | | 1 | | | — | | | — | | | — | |
Native Hawaiian or Pacific Islander | | | — | | | — | | | — | | | — | |
White | | | 1 | | | 6 | | | — | | | — | |
Two or More Races or Ethnicities | | | — | | | — | | | — | | | — | |
LGBTQ+ | | | — | | |||||||||
Did Not Disclose Demographic Background | | | 2 | |
| Board Diversity Matrix (As of March 31, 2023) | | ||||||||||||||||||||||||
| Total Number of Directors | | | 11 | | |||||||||||||||||||||
| | | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
| Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
| Directors | | | | | 2 | | | | | | 8 | | | | | | – | | | | | | 1 | | |
| Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
| African American or Black | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Alaskan Native or Native American | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Asian | | | | | – | | | | | | 1 | | | | | | – | | | | | | – | | |
| Hispanic or Latinx | | | | | 1 | | | | | | – | | | | | | – | | | | | | – | | |
| Native Hawaiian or Pacific Islander | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| White | | | | | 2 | | | | | | 8 | | | | | | – | | | | | | – | | |
| Two or More Races or Ethnicities | | | | | 1 | | | | | | – | | | | | | – | | | | | | – | | |
| LGBTQ+ | | | – | | |||||||||||||||||||||
| Did Not Disclose Demographic Background | | | – | |
| Board Diversity Matrix (As of April 1, 2022) | | ||||||||||||||||||||||||
| Total Number of Directors | | | 11 | | |||||||||||||||||||||
| | | | Female | | | Male | | | Non-Binary | | | Did Not Disclose Gender | | ||||||||||||
| Part I: Gender Identity | | | | | | | | | | | | | | | | | | | | | | | | | |
| Directors | | | | | 2 | | | | | | 8 | | | | | | – | | | | | | 1 | | |
| Part II: Demographic Background | | | | | | | | | | | | | | | | | | | | | | | | | |
| African American or Black | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Alaskan Native or Native American | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| Asian | | | | | – | | | | | | 1 | | | | | | – | | | | | | – | | |
| Hispanic or Latinx | | | | | 1 | | | | | | – | | | | | | – | | | | | | – | | |
| Native Hawaiian or Pacific Islander | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| White | | | | | 1 | | | | | | 6 | | | | | | – | | | | | | – | | |
| Two or More Races or Ethnicities | | | | | – | | | | | | – | | | | | | – | | | | | | – | | |
| LGBTQ+ | | | – | | |||||||||||||||||||||
| Did Not Disclose Demographic Background | | | 2 | |
Name | | | Board | | | Audit | | | Compensation | | | Nominating and Governance | | | Research and Development | |
Paolo Fundarò | | | C | | | – | | | – | | | – | | | – | |
Jerome Durso | | | M | | | – | | | – | | | – | | | – | |
Srinivas Akkaraju, M.D., Ph.D. | | | M | | | – | | | – | | | – | | | M | |
Luca Benatti, Ph.D. | | | M | | | – | | | – | | | C | | | M | |
Daniel Bradbury | | | M | | | M | | | – | | | M | | | – | |
Keith Gottesdiener, M.D. | | | M | | | – | | | – | | | – | | | C | |
Nancy Miller-Rich | | | M | | | – | | | M | | | M | | | – | |
Mark Pruzanski, M.D. | | | M | | | – | | | – | | | – | | | M | |
Dagmar Rosa-Bjorkeson | | | M | | | – | | | M | | | – | | | – | |
Gino Santini | | | M | | | M | | | C | | | – | | | – | |
Glenn Sblendorio | | | M | | | C | | | – | | | – | | | – | |
Membership | | | Chairperson | | | Other Members | | ||||||
Board of Directors. | | | | $ | 80,000 | | | | | $ | 50,000 | | |
Audit Committee | | | | $ | 20,000 | | | | | $ | 10,000 | | |
Compensation Committee | | | | $ | 15,000 | | | | | $ | 7,500 | | |
Nominating and Governance Committee | | | | $ | 10,000 | | | | | $ | 5,000 | | |
Research and Development Committee | | | | $ | 10,000 | | | | | $ | 5,000 | | |
Name | | Fees Earned or Paid in Cash ($)(2) | | Stock Awards ($)(3) | | Option Awards ($)(3) | | Total ($) | | | Fees Earned or Paid in Cash ($)(2) | | Stock Awards ($)(3) | | Option Awards ($)(3) | | Total ($) | | ||||||||||||||||||||||||||||||||
Paolo Fundarò | | | | 80,000 | | | | | 120,055 | | | | | 120,165 | | | | | 320,220 | | | | | | 80,000 | | | | | 130,136 | | | | | 132,249 | | | | | 342,385 | | | ||||||||
Jerome Durso(1) | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
Srinivas Akkaraju | | | | 55,000 | | | | | 120,055 | | | | | 120,165 | | | | | 295,220 | | | | | | 55,000 | | | | | 130,136 | | | | | 132,249 | | | | | 317,385 | | | ||||||||
Luca Benatti | | | | 65,000 | | | | | 120,055 | | | | | 120,165 | | | | | 305,220 | | | | | | 65,000 | | | | | 130,136 | | | | | 132,249 | | | | | 327,385 | | | ||||||||
Daniel Bradbury | | | | 65,000 | | | | | 120,055 | | | | | 120,165 | | | | | 305,220 | | | | | | 65,000 | | | | | 130,136 | | | | | 132,249 | | | | | 327,385 | | | ||||||||
Keith Gottesdiener | | | | 57,972 | | | | | 120,055 | | | | | 120,165 | | | | | 298,192 | | | | | | 60,000 | | | | | 130,136 | | | | | 132,249 | | | | | 322,385 | | | ||||||||
Nancy Miller-Rich | | | | 60,472 | | | | | 120,055 | | | | | 120,165 | | | | | 300,692 | | | | | | 62,500 | | | | | 130,136 | | | | | 132,249 | | | | | 324,885 | | | ||||||||
Mark Pruzanski(1) | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||
Dagmar Rosa-Bjorkeson | | | | 41,958 | | | | | 180,074 | | | | | 180,202 | | | | | 402,235 | | | | | | 57,500 | | | | | 130,136 | | | | | 132,249 | | | | | 319,885 | | | ||||||||
Gino Santini | | | | 75,000 | | | | | 120,055 | | | | | 120,165 | | | | | 315,220 | | | | | | 75,000 | | | | | 130,136 | | | | | 132,249 | | | | | 337,385 | | | ||||||||
Glenn Sblendorio | | | | 70,000 | | | | | 120,055 | | | | | 120,165 | | | | | 310,220 | | | | | | 70,000 | | | | | 130,136 | | | | | 132,249 | | | | | 332,385 | | | ||||||||
Daniel Welch(1) | | | | 27,375 | | | | | — | | | | | — | | | | | 27,375 | | |
Name | | | Shares Subject to Stock Options | | | RSUs | | ||||||
Paolo Fundarò | | | | | 27,616 | | | | | | 7,029 | | |
Srinivas Akkaraju | | | | | 26,615 | | | | | | 7,029 | | |
Luca Benatti | | | | | 25,912 | | | | | | 7,029 | | |
Daniel Bradbury | | | | | 25,209 | | | | | | 7,029 | | |
Keith Gottesdiener | | | | | 25,209 | | | | | | 7,029 | | |
Nancy Miller-Rich | | | | | 24,913 | | | | | | 7,029 | | |
Dagmar Rosa-Bjorkeson | | | | | 17,719 | | | | | | 10,543 | | |
Gino Santini | | | | | 27,111 | | | | | | 7,029 | | |
Glenn Sblendorio | | | | | 25,912 | | | | | | 7,029 | | |
Daniel Welch(1) | | | | | 15,022 | | | | | | — | | |
Name | | | Shares Subject to Stock Options | | | RSUs | | ||||||
Paolo Fundarò | | | | | 40,406 | | | | | | 7,737 | | |
Srinivas Akkaraju | | | | | 39,405 | | | | | | 7,737 | | |
Luca Benatti | | | | | 38,702 | | | | | | 7,737 | | |
Daniel Bradbury | | | | | 37,999 | | | | | | 7,737 | | |
Keith Gottesdiener | | | | | 37,999 | | | | | | 7,737 | | |
Nancy Miller-Rich | | | | | 37,703 | | | | | | 7,737 | | |
Dagmar Rosa-Bjorkeson | | | | | 30,509 | | | | | | 14,765 | | |
Gino Santini | | | | | 39,901 | | | | | | 7,737 | | |
Glenn Sblendorio | | | | | 38,702 | | | | | | 7,737 | | |
| | Shares Beneficially Owned | | | Shares Beneficially Owned | | ||||||||||||||||||||
Name and Address | | Number of Shares | | Percentage of Common Stock | | | Number of Shares | | Percentage of Common Stock | | ||||||||||||||||
5% Stockholders: | | | | | | | | | | | | | | | | | | | | | | | ||||
Genextra S.p.A.(1) | | | | 4,000,000 | | | | | 13.5% | | | | | | 4,000,000 | | | | | 9.6% | | | ||||
State Street Corporation(2) | | | | 3,254,266 | | | | | 11.0% | | | |||||||||||||||
FMR LLC(3) | | | | 2,639,433 | | | | | 8.9% | | | |||||||||||||||
The Vanguard Group(2) | | | | 3,637,935 | | | | | 8.7% | | | |||||||||||||||
State Street Corporation(3) | | | | 3,175,925 | | | | | 7.6% | | | |||||||||||||||
BlackRock, Inc.(4) | | | | 2,232,092 | | | | | 7.5% | | | | | | 3,084,833 | | | | | 7.4% | | | ||||
The Vanguard Group(5) | | | | 1,971,759 | | | | | 6.6% | | | |||||||||||||||
Directors and Executive Officers:(6) | | | | | | | | | | | | |||||||||||||||
Paolo Fundarò(1) | | | | 4,055,673 | | | | | 13.6% | | | |||||||||||||||
Directors and Executive Officers:(5) | | | | | | | | | | | | |||||||||||||||
Paolo Fundarò | | | | 76,200 | | | | | * | | | |||||||||||||||
Jerome Durso | | | | 123,168 | | | | | * | | | | | | 184,515 | | | | | * | | | ||||
Srinivas Akkaraju(7) | | | | 697,453 | | | | | 2.3% | | | |||||||||||||||
Srinivas Akkaraju(6) | | | | 717,980 | | | | | 1.7% | | | |||||||||||||||
Luca Benatti | | | | 43,662 | | | | | * | | | | | | 64,189 | | | | | * | | | ||||
Daniel Bradbury(8) | | | | 48,832 | | | | | * | | | |||||||||||||||
Daniel Bradbury(7) | | | | 69,359 | | | | | * | | | |||||||||||||||
Keith Gottesdiener | | | | 42,191 | | | | | * | | | | | | 62,718 | | | | | * | | | ||||
Nancy Miller-Rich | | | | 39,480 | | | | | * | | | | | | 60,007 | | | | | * | | | ||||
Mark Pruzanski | | | | 897,255 | | | | | 3.0% | | | | | | 867,172 | | | | | 2.1% | | | ||||
Dagmar Rosa-Bjorkeson | | | | 9,422 | | | | | * | | | | | | 39,369 | | | | | * | | | ||||
Gino Santini | | | | 43,019 | | | | | * | | | | | | 63,546 | | | | | * | | | ||||
Glenn Sblendorio | | | | 41,622 | | | | | * | | | | | | 62,149 | | | | | * | | | ||||
Andrew Saik(9) | | | | — | | | | | — | | | |||||||||||||||
Sandip Kapadia(10) | | | | 15,589 | | | | | * | | | |||||||||||||||
Rocco Venezia | | | | 18,235 | | | | | * | | | |||||||||||||||
Andrew Saik | | | | 55,682 | | | | | * | | | |||||||||||||||
Michelle Berrey | | | | 72,880 | | | | | * | | | |||||||||||||||
Linda Richardson | | | | 55,087 | | | | | * | | | |||||||||||||||
Jared Freedberg | | | | 32,897 | | | | | * | | | | | | 64,362 | | | | | * | | | ||||
Michelle Berrey(9) | | | | — | | | | | — | | | |||||||||||||||
Gail Cawkwell | | | | 54,211 | | | | | * | | | |||||||||||||||
All current directors and executive officers as a group (19 persons) | | | | 6,244,785 | | | | | 21.0% | | | |||||||||||||||
All current directors and executive officers as a group (17 persons) | | | | 2,599,252 | | | | | 6.2% | | |
| Mr. Fundarò | | | Mr. Durso | | |||
| Dr. | | | | ||||
| | | Dr. | | ||||
| | | | |||||
| | | Mr. | | ||||
| | | Mr. Saik (40,624 shares), | | ||||
| Dr. | | | Ms. Richardson (38,381 shares), | | |||
| Mr. Freedberg (47,670 shares), and | | | |||||
| all directors and executive officers as a group (1,024,865 shares). | |
Name | | | Age | | | Position | |
| | | | Chief | | ||
M. Michelle Berrey, M.D., | | | | | President of Research & Development; Chief Medical Officer | | |
| | 59 | | | | ||
Jared Freedberg | | | 54 | | | General Counsel | |
David Ford | | | | | Chief Human Resources Officer | ||
| |||||||
Rocco Venezia | | | | | Chief Accounting Officer | |
Name | | | Title | |
Jerome Durso | | | President and Chief Executive Officer | |
Andrew Saik | | | Chief Financial Officer | |
| ||||
M. Michelle Berrey, M.D., M.P.H. | | | President of Research & Development; Chief Medical Officer | |
| | | ||
Jared Freedberg | | | General Counsel | |
| | | | |
| | | | |
| | ✓ Steady Growth in Ocaliva Net Sales. Our Ocaliva net sales in the United States have risen from $18.2 million in 2016 to ✓ Management Alignment Behind Value Creation. In | | |
| | Key Business Achievements | | | ||||||||||||
| | ✓ | | | | Sustainable and Growing PBC Business, | | | ||||||||
| | ✓ | | | | |||||||||||
Leveraged Commercial Strengths. We leveraged our commercial strengths, and focused from a sales perspective on specialty product distribution, payor coverage, community education, deep relationships in the liver community, and (due to the COVID-19 pandemic) expanded use of virtual communications | | | ||||||||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | | | |||||||||
| | ✓ | | | | Progressing OCA for Pre-Cirrhotic Liver Fibrosis Due to NASH. In December 2022, we resubmitted our NDA to the FDA. The FDA subsequently accepted the NDA and assigned a Prescription Drug User Fee Act (“PDUFA”) target action date of June 22, 2023. Our NDA is supported by a robust body of evidence from our OCA NASH clinical development program, including two positive interim analyses from our Phase 3 REGENERATE study. | | | ||||||||
| | ✓ | | | | Advancing Internal Pipeline in | ||||||||||
| |
| | CEO Compensation Highlights | | | ||||||||||||
| | Mr. Jerome Durso became our Chief Executive Officer on January 1, 2021. Previously, he was our Chief Operating Officer. Mr. Durso has been with Intercept since 2017, and has over 25 years of life sciences experience, including in operational, managerial, marketing, and sales positions. | | | ||||||||||||
| | Mr. Durso leads a highly experienced executive leadership team, and his compensation in both | | |
| | Compensation and Governance Best Practices | | | ||||||||||||
| | What We Do | | | ||||||||||||
| | ✓ | | | | Independent Chairman and Majority Independent Board. Paolo Fundarò serves as our Board’s Chairman, and all of the members of our Board other than our current CEO (Mr. Durso), and our founder and retired CEO (Dr. Pruzanski) are independent directors. | | | ||||||||
| | ✓ | | | | |||||||||||
Independent Compensation Committee. Our Compensation Committee, which is composed entirely of independent directors, provides independent oversight of our compensation programs. | | | ||||||||||||||
| | ✓ | | | | Independent Compensation Consultant. Our Compensation Committee uses an independent executive compensation consulting firm that reports directly to the Compensation Committee. | | | ||||||||
| | ✓ | | | | Annual Compensation Review and Analysis. Our Compensation Committee conducts an annual assessment of executive compensation to ensure that we provide competitive compensation packages to attract, retain, reward, and incentivize our executive management team to achieve success for us and our stockholders. | | | ||||||||
| | ✓ | | | | Multiple Performance Elements. In accordance with our performance-based compensation philosophy, our executive compensation program incorporates multiple performance elements, including target-based cash incentive bonuses payable upon the achievement of corporate goals and individual performance, and long-term equity incentive compensation, a substantial portion of which consists of stock options and PSUs. | | | ||||||||
| | ✓ | | | | Significant Portion of Compensation Is at Risk. Under our executive compensation program, a significant portion of compensation is “at risk” based on our performance, including annual cash incentive bonuses, and long-term incentive compensation in the form of equity awards, to align the interests of our executive officers and stockholders. | | | ||||||||
| | ✓ | | | | Market Benchmarking and Use of Reference Peer Group. Our Compensation Committee, with the assistance of its independent compensation consultant, annually analyzes similar life science companies to identify a relevant group of peer companies for purposes of ensuring the reasonableness and competitiveness of our executive compensation program. | | | ||||||||
| | ✓ | | | | Stock Ownership Requirements. We have adopted minimum stock ownership guidelines for our Board, Chief Executive Officer, and other executive officers, including our named executive officers, which require, within specified periods of time, our non-employee directors to hold Company equity with a value equal to at least 3x their annual cash retainer, and our Chief Executive Officer and other executive officers to hold Company equity with a value equal to at least 3x and 1x, respectively, their annual base salary. | | |
| | ✓ | | | | Clawback Policy. We have adopted a clawback policy that permits the Company to recover from any current or former executive officer, including any named executive officer, whose fraud or intentional misconduct contributes to the circumstances requiring the Company to prepare an accounting restatement due to material non-compliance of the Company with any financial reporting requirement under U.S. federal securities laws, up to 100% of any incentive-based compensation, including equity compensation, received by such officer from the Company during the one-year period preceding the date on which the Company is required to prepare such accounting restatement. | | |
| | ✓ | | | | Corporate Governance Guidelines. | | | ||||||||
| | What We Don’t Do | | | ||||||||||||
| | ✘ | | | | No excise tax gross-ups. We have not provided, or committed to provide, excise tax gross-ups to any of our named executive officers. | | | ||||||||
| | ✘ | | | | No change in control “windfalls”. The change in control protections for our named executive officers are limited to “double-trigger” arrangements, which require both a change in control and a qualifying termination of employment, or in the case of PSUs, vesting, if at all, based on our TSR performance relative to that of our TSR Peer Group through the month preceding the month in which the change in control occurs. | | | ||||||||
| | ✘ | | | | Limited perquisites. Our named executive officers generally receive the same benefits as are available to all of our salaried employees, with limited recurring exceptions primarily consisting of fully-paid health insurance premiums. | | | ||||||||
| | ✘ | | | | No automatic or guaranteed annual salary increases. We do not provide for any formulaic or guaranteed base salary increases for our named executive officers. | | | ||||||||
| | ✘ | | | | No guaranteed bonuses or annual equity grants. We do not provide guaranteed bonuses or annual equity grants to our named executive officers. | | | ||||||||
| | ✘ | | | | No hedging or pledging of Company stock. Our named executive officers and other employees are restricted from engaging in speculative trading activities, including hedging or pledging Company securities as collateral. | | | ||||||||
| | ✘ | | | | No evergreen provision. Our equity compensation plan requires a shareholder vote for new equity requests and does not contain an evergreen provision. | | |
| Key areas of stockholder focus | | | Our responses | | |
| ||||||
During the course of our investor outreach, we explained the challenges of delivering competitive executive compensation, particularly with regards to long-term incentives, in a period where our stock price has been depressed for a sustained period of time. These challenges impact both the attraction of new executive talent, and also the retention and incentivization of existing executives. We shared that, in response to these challenges, the Company has had to deploy new and innovative compensation tools in Investors clearly understood the challenges facing the Company and the competitive pressures driving the needs for innovation in compensation, and requested an explanation of compensation measures implemented, including their usage and effectiveness. | | | In relation to this request, this Compensation Discussion and Analysis (“CD&A”) contains detailed explanations of (where applicable) the new hire awards issued to attract new executives, and the | | ||
| Investors whom we spoke with were highly complimentary of our executive compensation disclosures, particularly the CD&A portions of our recent proxy statements with respect to comprehensiveness, transparency, and clear explanations of our corporate goals for purposes of payout under our annual cash incentive bonus program. Investors encouraged us to continue these disclosure practices, and improve them further where possible. | | | In this proxy statement, as in prior years, we continue to seek to provide useful disclosures to investors, including the calculations used to establish payout levels for our | |
| | | | | | |||
| | | Heron Therapeutics Inc. | | | | ||
| | | Ironwood Pharmaceuticals, Inc. | | | Puma Biotechnology, Inc. | | |
| Coheres BioSciences, Inc. | | | Ligand Pharmaceuticals Incorporated | | | | |
| | | ||||||
| | Supernus Pharmaceuticals, Inc. | | |||||
| Esperion Therapeutics, Inc. | | | | | Vanda Pharmaceuticals Inc. | |
| Aerie Pharmaceuticals, Inc. | | | Esperion Therapeutics, Inc. | | | Prothena Corporation plc | | ||
| Akebia Therapeutics, Inc. | | | FibroGen, Inc. | | | Puma Biotechnology, Inc. | | ||
| Amarin Corporation | | | Heron Therapeutics Inc. | | | Radius Health, Inc. | | ||
| ANI Pharmaceuticals, Inc. | | | Ironwood Pharmaceuticals, Inc. | | | Supernus Pharmaceuticals, Inc. | | ||
| bluebird bio, Inc. | | | Karyopharm Therapeutics | | | UniQure N.V. | | ||
| Coheres Biosciences, Inc. | | | Ligand Pharmaceuticals Incorporated | | | Vanda Pharmaceuticals Inc. | | ||
| Collegium Pharmaceutical, Inc. | | | | | | | |
Name | | 2022 ($) | | 2021 ($) | | 2020 ($) | | Change 2021 to 2022 (%) | | Change 2020 to 2021 (%) | | | 2023 ($) | | 2022 ($) | | 2021 ($) | | Change 2022 to 2023 (%) | | Change 2021 to 2022 (%) | | ||||||||||||||||||||||||||||||||||||||||
Jerome Durso | | | | 717,000 | | | | | 690,750 | | | | | 601,913 | | | | | 3.80% | | | | | 14.76% | | | | | | 752,850 | | | | | 717,000 | | | | | 690,750 | | | | | 5.00% | | | | | 3.80% | | | ||||||||||
Andrew Saik | | | | 493,000 | | | | | 475,000 | | | | | — | | | | | 3.79% | | | | | N/A | | | | | | 512,720 | | | | | 493,000 | | | | | 475,000 | | | | | 4.00% | | | | | 3.79% | | | ||||||||||
Sandip Kapadia | | | | — | | | | | 497,140 | | | | | 478,023 | | | | | N/A | | | | | 4.00% | | | ||||||||||||||||||||||||||||||||||||
Rocco Venezia | | | | 381,500 | | | | | 318,010 | | | | | 308,000 | | | | | 19.96% | | | | | 3.25% | | | ||||||||||||||||||||||||||||||||||||
Michelle Berrey | | | | 647,400 | | | | | 622,500 | | | | | 600,000 | | | | | 4.00% | | | | | 3.75% | | | ||||||||||||||||||||||||||||||||||||
Linda Richardson | | | | 517,920 | | | | | 498,000 | | | | | 480,000 | | | | | 4.00% | | | | | 3.75% | | | ||||||||||||||||||||||||||||||||||||
Jared Freedberg | | | | 479,000 | | | | | 461,600 | | | | | — | | | | | 3.77% | | | | | N/A | | | | | | 498,160 | | | | | 479,000 | | | | | 461,600 | | | | | 4.00% | | | | | 3.77% | | | ||||||||||
Michelle Berrey | | | | 622,500 | | | | | 600,000 | | | | | — | | | | | 3.75% | | | | | N/A | | | ||||||||||||||||||||||||||||||||||||
Gail Cawkwell | | | | 498,000 | | | | | 479,950 | | | | | 461,492 | | | | | 3.76% | | | | | 4.00% | | |
Goal | | | Weight | | | Performance Score | | | Weighted Performance | | |||||||||
Achieve PBC net sales of $395 million* | | | | | 50% | | | | | | 102.0% | | | | | | 17.85% | | |
Achieve PBC commercial contribution of $165 million* | | | | | 25% | | | | | | 106.5% | | | | | | 9.32% | | |
Submit comprehensive benefit-risk data package to the European Medicines Agency (“EMA”)* | | | | | 25% | | | | | | 100.0% | | | | | | 8.75% | | |
PBC (total) | | | | | 35% | | | | | | 102.6% | | | | | | 35.92% | | |
Report topline results from the re-analysis of efficacy data from the updated REGENERAGE interim analysis | | | | | 25% | | | | | | 97.5% | | | | | | 9.75% | | |
Report topline results of the REVERSE study | | | | | 25% | | | | | | 100.0% | | | | | | 10.00% | | |
Prepare a go/no-go recommendation on the NASH resubmission | | | | | 50% | | | | | | 100.0% | | | | | | 20.00% | | |
If the recommendation is to resubmit, resubmitting by year-end 2022 results in a 50% additional multiplier to the NASH goals | | | | | N/A | | | | | | N/A | | | | | | 19.88% | | |
NASH (total) | | | | | 40% | | | | | | 149.1% | | | | | | 59.63% | | |
Achieve interim read-out for Studies #123, 213, and 214 to support a go/no-go decision for the OCA/bezafibrate FDC | | | | | 50% | | | | | | 80.0% | | | | | | 4.00% | | |
Achieve first patient in (“FPI”) for bezafibrate Study #977-113 | | | | | 20% | | | | | | 100.0% | | | | | | 2.00% | | |
Achieve first patient dose in proof of concept Study #787-201 | | | | | 30% | | | | | | 80.0% | | | | | | 2.40% | | |
Advance portfolio expansion (total) | | | | | 10% | | | | | | 84.0% | | | | | | 8.40% | | |
Operational readiness and strategic planning goals, including a 50% additional multiplier if the company completes a substantial business development transaction** | | | | | 100% | | | | | | 150.0% | | | | | | 22.50% | | |
Operational readiness (total) | | | | | 15% | | | | | | 150.0% | | | | | | 22.50% | | |
Grand total | | | | | 100% | | | | | | 126.43% | | | | | | 126.43% | | |
Goal | | | Weight | | | Performance Score | | | Weighted Performance | | |||||||||
Achieve PBC net sales of $332.5 million | | | | | 50% | | | | | | 117.80% | | | | | | 29.45% | | |
Achieve PBC commercial contribution of $102 million | | | | | 15% | | | | | | 200.00% | | | | | | 15.00% | | |
Complete enrollment for Study 213 by year-end | | | | | 10% | | | | | | 44.40% | | | | | | 2.22% | | |
Deliver first topline results from Study 123 by year-end | | | | | 10% | | | | | | 0.00% | | | | | | 0.00% | | |
Achieve regulatory alignment on post-marketing commitments for PBC by year-end | | | | | 15% | | | | | | 100.00% | | | | | | 7.50% | | |
PBC total | | | | | 50% | | | | | | 108.34% | | | | | | 54.17% | | |
Advance the delivery of the analyses necessary to support the decision-making process on OCA in NASH by year-end | | | | | 60% | | | | | | 75.00% | | | | | | 18.00% | | |
Achieve last patient visit in REVERSE/Study 304 by end Q3 2021 | | | | | 20% | | | | | | 100.00% | | | | | | 8.00% | | |
Deliver topline safety and efficacy readout of REVERSE/Study 304 by year-end | | | | | 20% | | | | | | 0.00% | | | | | | 0.00% | | |
NASH total | | | | | 40% | | | | | | 65.00% | | | | | | 26.00% | | |
Strategy and pipeline goals including commencing first in human study of INT-787 by year-end | | | | | 100% | | | | | | 100.00% | | | | | | 10.00% | | |
Strategy and pipeline total | | | | | 10% | | | | | | 100.00% | | | | | | 10.00% | | |
Total | | | | | 100% | | | | | | 90.17% | | | | | | 90.17% | | |
| | | 2021 | | | 2022 Target | | ||||||||||||||||||||||||||||||
Name | | | Target | | | Corporate Performance | | | Individual Performance | | | Payout | | | Payout ($) | | |||||||||||||||||||||
Jerome Durso | | | | | 70% | | | | | | 90.17% | | | | | | N/A | | | | | | 63.119% | | | | | | 435,994.49 | | | | | | 70% | | |
Andrew Saik | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 113,822.72 | | | | | | 50% | | |
Sandip Kapadia | | | | | N/A | | | | | | N/A | | | | | | N/A | | | | | | N/A | | | | | | N/A | | | | | | N/A | | |
Rocco Venezia | | | | | 40% | | | | | | 90.17% | | | | | | 100% | | | | | | 36.068% | | | | | | 131,648.20 | | | | | | 50% | | |
Jared Freedberg | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 208,112.36 | | | | | | 50% | | |
Michelle Berrey | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 148,969.86 | | | | | | 50% | | |
Gail Cawkwell | | | | | 50% | | | | | | 90.17% | | | | | | 100% | | | | | | 45.085% | | | | | | 216,385.46 | | | | | | 50% | | |
| | | 2022 | | | 2023 Target | | ||||||||||||||||||||||||||||||
Name | | | Target | | | Corporate Performance | | | Individual Performance | | | Payout | | | Payout ($) | | |||||||||||||||||||||
Jerome Durso | | | | | 70% | | | | | | 126.43% | | | | | | N/A | | | | | | 88.501% | | | | | | 634,552.17 | | | | | | 70% | | |
Andrew Saik | | | | | 50% | | | | | | 126.43% | | | | | | 120% | | | | | | 75.858% | | | | | | 373,979.94 | | | | | | 50% | | |
Michelle Berrey | | | | | 50% | | | | | | 126.43% | | | | | | 120% | | | | | | 75.858% | | | | | | 472,216.05 | | | | | | 50% | | |
Linda Richardson | | | | | 50% | | | | | | 126.43% | | | | | | 103% | | | | | | 65.111% | | | | | | 324,255.02 | | | | | | 50% | | |
Jared Freedberg | | | | | 50% | | | | | | 126.43% | | | | | | 103% | | | | | | 65.111% | | | | | | 311,883.85 | | | | | | 50% | | |
| | 2021 | | 2022 | | | 2022 | | 2023 | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Options | | RSUs | | PSUs | | Options | | RSUs | | PSUs | | | Options | | RSUs | | PSUs | | Options | | RSUs | | PSUs | | ||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso | | | | 72,000 | | | | | 46,000 | | | | | 110,300 | | | | | 60,900 | | | | | 35,700 | | | | | 107,000 | | | | | | 60,900 | | | | | 35,700 | | | | | 107,000 | | | | | 82,700 | | | | | 50,400 | | | | | 151,300 | | | ||||||||||||
Andrew Saik | | | | 72,540 | | | | | 52,156 | | | | | — | | | | | 17,600 | | | | | 10,300 | | | | | 10,300 | | | | | | 17,600 | | | | | 10,300 | | | | | 10,300 | | | | | 24,000 | | | | | 14,700 | | | | | 14,700 | | | ||||||||||||
Sandip Kapadia | | | | 26,900 | | | | | 17,200 | | | | | 13,800 | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||
Rocco Venezia | | | | 5,500 | | | | | 3,438 | | | | | — | | | | | 6,100 | | | | | 3,600 | | | | | 3,600 | | | |||||||||||||||||||||||||||||||||||||||||||
Michelle Berrey | | | | 17,600 | | | | | 10,300 | | | | | 10,300 | | | | | 24,000 | | | | | 14,700 | | | | | 14,700 | | | |||||||||||||||||||||||||||||||||||||||||||
Linda Richardson | | | | 17,600 | | | | | 10,300 | | | | | 10,300 | | | | | 20,000 | | | | | 12,200 | | | | | 12,200 | | | |||||||||||||||||||||||||||||||||||||||||||
Jared Freedberg | | | | 69,400 | | | | | 44,277 | | | | | — | | | | | 17,600 | | | | | 10,300 | | | | | 10,300 | | | | | | 17,600 | | | | | 10,300 | | | | | 10,300 | | | | | 20,000 | | | | | 12,200 | | | | | 12,200 | | | ||||||||||||
Michelle Berrey | | | | 93,000 | | | | | 67,118 | | | | | — | | | | | 17,600 | | | | | 10,300 | | | | | 10,300 | | | |||||||||||||||||||||||||||||||||||||||||||
Gail Cawkwell | | | | 19,700 | | | | | 12,600 | | | | | 10,100 | | | | | 11,300 | | | | | 6,600 | | | | | 6,600 | | |
Name and Principal Position(1) | | Year | | Salary ($) | | Bonus ($)(2) | | Stock Awards ($)(3) | | Option Awards ($)(3) | | Non-Equity Incentive Plan Compensation ($)(4) | | All Other Compensation ($)(5) | | Total ($) | | | Year | | Salary ($) | | Bonus ($)(2) | | Stock Awards ($)(3) | | Option Awards ($)(3) | | Non-Equity Incentive Plan Compensation ($)(4) | | All Other Compensation ($)(5) | | Total ($) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso, President & CEO | | | | | 2021 | | | | | 690,750 | | | | | — | | | | | 5,474,865 | | | | | 1,234,800 | | | | | 435,994 | | | | | 33,945 | | | | | 7,870,354 | | | | | | | 2022 | | | | | 714,813 | | | | | — | | | | | 2,547,438 | | | | | 535,540 | | | | | 634,552 | | | | | 23,120 | | | | | 4,455,463 | | | ||||||||||||||
| | | 2020 | | | | | 599,524 | | | | | — | | | | | 2,057,016 | | | | | 998,776 | | | | | 231,737 | | | | | 21,910 | | | | | 3,908,963 | | | | | | 2021 | | | | | 690,750 | | | | | — | | | | | 5,474,865 | | | | | 1,234,800 | | | | | 435,994 | | | | | 33,945 | | | | | 7,870,354 | | | |||||||||||||||||
| | | 2019 | | | | | 573,250 | | | | | — | | | | | 2,089,570 | | | | | 1,238,321 | | | | | 359,284 | | | | | 21,368 | | | | | 4,281,793 | | | | | | 2020 | | | | | 599,524 | | | | | — | | | | | 2,057,016 | | | | | 998,776 | | | | | 231,737 | | | | | 21,910 | | | | | 3,908,963 | | | |||||||||||||||||
Andrew Saik, CFO | | | | 2021 | | | | | 251,894 | | | | | 102,500 | | | | | 1,086,931 | | | | | 903,848 | | | | | 113,823 | | | | | 16,857 | | | | | 2,475,854 | | | | | | | 2022 | | | | | 491,500 | | | | | — | | | | | 344,329 | | | | | 154,770 | | | | | 373,980 | | | | | 23,120 | | | | | 1,387,699 | | | |||||||||||||||
Sandip Kapadia, Former CFO | | | | | 2021 | | | | | 117,513 | | | | | — | | | | | 1,022,142 | | | | | 461,335 | | | | | — | | | | | 59,674 | | | | | 1,660,664 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2020 | | | | | 476,863 | | | | | — | | | | | 1,087,836 | | | | | 528,088 | | | | | 184,039 | | | | | 21,910 | | | | | 2,298,736 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2019 | | | | | 464,100 | | | | | — | | | | | 1,001,664 | | | | | 586,573 | | | | | 252,935 | | | | | 21,368 | | | | | 2,326,640 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rocco Venezia, Interim CFO & Chief Accounting Officer | | | | 2021 | | | | | 354,554 | | | | | 154,000 | | | | | 101,283 | | | | | 94,325 | | | | | 131,648 | | | | | 20,423 | | | | | 856,234 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Andrew Saik, CFO | | | | | 2021 | | | | | 251,894 | | | | | 102,500 | | | | | 1,086,931 | | | | | 903,848 | | | | | 113,823 | | | | | 16,857 | | | | | 2,475,854 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2022 | | | | | 620,625 | | | | | — | | | | | 344,329 | | | | | 154,770 | | | | | 472,216 | | | | | 22,305 | | | | | 1,614,245 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michelle Berrey, President of R&D and Chief Medical Officer | | | | | 2021 | | | | | 329,545 | | | | | — | | | | | 1,434,983 | | | | | 1,186,680 | | | | | 148,970 | | | | | 18,321 | | | | | 3,118,499 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2022 | | | | | 496,500 | | | | | — | | | | | 344,329 | | | | | 154,770 | | | | | 324,255 | | | | | 16,975 | | | | | 1,336,829 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jared Freedberg, General Counsel | | | | 2021 | | | | | 423,133 | | | | | — | | | | | 1,633,821 | | | | | 1,487,242 | | | | | 208,112 | | | | | 21,714 | | | | | 3,774,023 | | | | | | | 2022 | | | | | 477,550 | | | | | — | | | | | 344,329 | | | | | 154,770 | | | | | 311,884 | | | | | 23,120 | | | | | 1,311,653 | | | |||||||||||||||
Michelle Berrey, President of R&D and Chief Medical Officer | | | | 2021 | | | | | 329,545 | | | | | — | | | | | 1,434,983 | | | | | 1,186,680 | | | | | 148,970 | | | | | 18,321 | | | | | 3,118,499 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gail Cawkwell, SVP Medical Affairs, Safety & Pharmacovigilance | | | | 2021 | | | | | 478,412 | | | | | 750,000 | | | | | 748,431 | | | | | 337,855 | | | | | 216,385 | | | | | 31,244 | | | | | 2,562,328 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jared Freedberg, General Counsel | | | | | 2021 | | | | | 423,133 | | | | | — | | | | | 1,633,821 | | | | | 1,487,242 | | | | | 208,112 | | | | | 21,714 | | | | | 3,774,023 | | |
Name | | Contributions Under Retirement Plans ($)(i) | | Health Insurance ($)(ii) | | Miscellaneous | | | Contributions Under Retirement Plans ($)(i) | | Health Insurance ($)(ii) | | ||||||||||||||||||||
Jerome Durso | | | | 14,500 | | | | | 7,870 | | | | | 11,575 | | | | | | 15,250 | | | | | 7,870 | | | |||||
Andrew Saik | | | | 12,595 | | | | | 4,263 | | | | | — | | | | | | 15,250 | | | | | 7,870 | | | |||||
Sandip Kapadia | | | | — | | | | | 1,967 | | | | | 57,706 | | | ||||||||||||||||
Rocco Venezia | | | | 14,500 | | | | | — | | | | | 5,923 | | | ||||||||||||||||
Michelle Berrey | | | | 15,250 | | | | | 7,055 | | | |||||||||||||||||||||
Linda Richardson | | | | 15,250 | | | | | 1,725 | | | |||||||||||||||||||||
Jared Freedberg | | | | 14,500 | | | | | 7,214 | | | | | — | | | | | | 15,250 | | | | | 7,870 | | | |||||
Michelle Berrey | | | | 14,500 | | | | | 3,822 | | | | | — | | | ||||||||||||||||
Gail Cawkwell | | | | 14,500 | | | | | 7,870 | | | | | 8,875 | | |
Name | | Grant Date(1) | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(3) | | | All Other Stock Awards: Number of Shares of Stock (#)(4) | | All Other Option Awards: Number of Securities Underlying Options (#)(5) | | Exercise or Base Price of Option Awards ($/Sh)(6) | | Grant Date Fair Value of Stock and Option Awards ($)(7) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Estimated Future Payouts Under Equity Incentive Plan Awards(3) | | | All Other Stock Awards: Number of Shares of Stock (#)(4) | | All Other Option Awards: Number of Securities Underlying Options (#)(5) | | Exercise or Base Price of Option Awards ($/Sh)(6) | | Grant Date Fair Value of Stock and Option Awards ($)(7) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Grant Date(1) | | Estimated Future Payout Under Non-Equity Incentive Plan Awards Target ($)(2) | | | Threshold (#) | | Target (#) | | Maximum (#) | | | All Other Stock Awards: Number of Shares of Stock (#)(4) | | All Other Option Awards: Number of Securities Underlying Options (#)(5) | | Exercise or Base Price of Option Awards ($/Sh)(6) | | Grant Date Fair Value of Stock and Option Awards ($)(7) | | | Grant Date(1) | | | Threshold (#) | | Target (#) | | Maximum (#) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | — | | | | | — | | | | | — | | | | | | | — | | | | | 501,900 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso | | | | | 01/22/21 | | | | | — | | | | | 55,150 | | | | | 110,300 | | | | | 165,450 | | | | | — | | | | | — | | | | | — | | | | | 4,119,705 | | | | | | 01/27/22 | | | | | — | | | | | 53,500 | | | | | 107,000 | | | | | 160,500 | | | | | — | | | | | — | | | | | — | | | | | 2,031,930 | | | |||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 46,000 | | | | | — | | | | | — | | | | | 1,355,160 | | | | | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 35,700 | | | | | — | | | | | — | | | | | 515,508 | | | |||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 72,000 | | | | | 29.46 | | | | | 1,234,800 | | | | | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 60,900 | | | | | 14.44 | | | | | 535,540 | | | |||||||||||||||||||
| | | — | | | | | 237,500 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | 246,500 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||
Andrew Saik | | | | | 06/21/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 01/27/22 | | | | | — | | | | | 5,150 | | | | | 10,300 | | | | | 15,450 | | | | | — | | | | | — | | | | | — | | | | | 195,597 | | | |||||||||||||||||
| | | 06/21/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 52,156 | | | | | — | | | | | — | | | | | 1,086,931 | | | | | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,300 | | | | | — | | | | | — | | | | | 148,732 | | | |||||||||||||||||||
| | | 06/21/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 72,540 | | | | | 20.84 | | | | | 903,848 | | | | | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,600 | | | | | 14.44 | | | | | 154,770 | | | |||||||||||||||||||
| | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sandip Kapadia | | | | | 01/22/21 | | | | | — | | | | | 6,900 | | | | | 13,800 | | | | | 20,700 | | | | | — | | | | | — | | | | | — | | | | | 515,430 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,200 | | | | | — | | | | | — | | | | | 506,712 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 26,900 | | | | | 29.46 | | | | | 461,335 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | — | | | | | 146,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rocco Venezia | | | | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 3,438 | | | | | — | | | | | — | | | | | 101,283 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 5,500 | | | | | 29.46 | | | | | 94,325 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 311,250 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michelle Berrey | | | | 01/27/22 | | | | | — | | | | | 5,150 | | | | | 10,300 | | | | | 15,450 | | | | | — | | | | | — | | | | | — | | | | | 195,597 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,300 | | | | | — | | | | | — | | | | | 148,732 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,600 | | | | | 14.44 | | | | | 154,770 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 249,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Linda Richardson | | | | 01/27/22 | | | | | — | | | | | 5,150 | | | | | 10,300 | | | | | 15,450 | | | | | — | | | | | — | | | | | — | | | | | 195,597 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,300 | | | | | — | | | | | — | | | | | 148,732 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,600 | | | | | 14.44 | | | | | 154,770 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 230,800 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | 239,500 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||
Jared Freedberg | | | | 02/01/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 01/27/22 | | | | | — | | | | | 5,150 | | | | | 10,300 | | | | | 15,450 | | | | | — | | | | | — | | | | | — | | | | | 195,597 | | | ||||||||||||||||||
| | | 02/01/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 44,277 | | | | | — | | | | | — | | | | | 1,633,821 | | | | | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 10,300 | | | | | — | | | | | — | | | | | 148,732 | | | |||||||||||||||||||
| | | 02/01/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 69,400 | | | | | 36.90 | | | | | 1,487,242 | | | | | | 01/27/22 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 17,600 | | | | | 14.44 | | | | | 154,770 | | | |||||||||||||||||||
| | | | — | | | | | 300,000 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Michelle Berrey | | | | 06/14/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/14/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 67,118 | | | | | — | | | | | — | | | | | 1,434,983 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 06/14/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 93,000 | | | | | 21.38 | | | | | 1,186,680 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | — | | | | | 239,975 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gail Cawkwell | | | | 01/22/21 | | | | | — | | | | | 5,050 | | | | | 10,100 | | | | | 15,150 | | | | | — | | | | | — | | | | | — | | | | | 377,235 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 12,600 | | | | | — | | | | | — | | | | | 371,196 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 01/22/21 | | | | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | 19,700 | | | | | 29.46 | | | | | 337,855 | | |
| | Option awards | | | | Stock awards | | | Option awards | | | | Stock awards | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name | | Number of securities underlying unexercised options (#) exercisable(2) | | Number of securities underlying unexercised options (#) unexercisable(2)(3) | | Equity incentive plan awards: number of securities underlying unexercised unearned options (#) | | Option exercise price ($) | | Option expiration date | | | | Number of shares or units of stock that have not vested (#)(3)(4) | | Market value of shares or units of stock that have not vested ($) | | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)(3)(5)(6) | | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($)(6) | | | Number of securities underlying unexercised options (#) exercisable(1) | | Number of securities underlying unexercised options (#) unexercisable(1)(2) | | Equity incentive plan awards: number of securities underlying unexercised unearned options (#) | | Option exercise price ($) | | Option expiration date | | | | Number of shares or units of stock that have not vested (#)(2)(3) | | Market value of shares or units of stock that have not vested ($) | | Equity incentive plan awards: number of unearned shares, units or other rights that have not vested (#)(2)(4)(5) | | Equity incentive plan awards: market or payout value of unearned shares, units or other rights that have not vested ($)(5) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(a) | | (b) | | (c) | | (d) | | (e) | | (f) | | | | (g) | | (h) | | (i) | | (j) | | | (b) | | (c) | | (d) | | (e) | | (f) | | | | (g) | | (h) | | (i) | | (j) | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jerome Durso | | | | | 20,000(a) | | | | | — | | | | | — | | | | | 115.93 | | | | | 02/23/27 | | | | | | | 850(a) | | | | | 13,847 | | | | | 3,750(a) | | | | | 61,088 | | | | | | | 20,000(a) | | | | | — | | | | | — | | | | | 115.93 | | | | | 02/23/27 | | | | | | | 2,650(a) | | | | | 32,781 | | | | | 4,250(a) | | | | | 52,573 | | | ||||||||||||||
| | | 20,267(b) | | | | | 433 | | | | | — | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 2,350(b) | | | | | 38,282 | | | | | 4,250(b) | | | | | 69,233 | | | | | | 20,700(b) | | | | | — | | | | | — | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 23,000(b) | | | | | 284,510 | | | | | 55,150(b) | | | | | 682,206 | | | |||||||||||||||||
| | | 11,400(c) | | | | | 3,800 | | | | | — | | | | | 110.80 | | | | | 01/16/29 | | | | | | | 5,300(c) | | | | | 86,337 | | | | | 55,150(c) | | | | | 898,394 | | | | | | 15,200(c) | | | | | — | | | | | — | | | | | 110.80 | | | | | 01/16/29 | | | | | | | 26,775(c) | | | | | 331,207 | | | | | 53,500(c) | | | | | 661,795 | | | |||||||||||||||||
| | | 8,700(d) | | | | | 8,700 | | | | | — | | | | | 99.66 | | | | | 01/23/30 | | | | | | | 34,500(d) | | | | | 562,005 | | | | | — | | | | | — | | | | | | 13,050(d) | | | | | 4,350 | | | | | — | | | | | 99.66 | | | | | 01/23/30 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||
| | | 18,000(e) | | | | | 54,000 | | | | | — | | | | | 29.46 | | | | | 01/22/31 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | 36,000(e) | | | | | 36,000 | | | | | — | | | | | 29.46 | | | | | 01/22/31 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||
Jerome Durso | | | | 15,225(f) | | | | | 45,675 | | | | | — | | | | | 14.44 | | | | | 01/27/32 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | —(f) | | | | | 72,540 | | | | | — | | | | | 20.84 | | | | | 06/21/31 | | | | | | | 52,156(e) | | | | | 849,621 | | | | | — | | | | | — | | | | | | | 27,202(g) | | | | | 45,338 | | | | | — | | | | | 20.84 | | | | | 06/21/31 | | | | | | | 32,598(d) | | | | | 403,237 | | | | | 5,150(c) | | | | | 63,706 | | | ||||||||||||||||
| | | — | | | | | — | | | | | — | | | | | — | | | | | — | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 2,050(g) | | | | | — | | | | | — | | | | | 148.73 | | | | | 07/15/26 | | | | | | | 88(a) | | | | | 1,434 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1,200(h) | | | | | — | | | | | — | | | | | 112.69 | | | | | 02/09/27 | | | | | | | 207(b) | | | | | 3,372 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 2,153(b) | | | | | 47 | | | | | — | | | | | 58.74 | | | | | 02/05/28 | | | | | | | 900(c) | | | | | 14,661 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rocco Venezia | | | | 990(c) | | | | | 330 | | | | | — | | | | | 110.80 | | | | | 01/16/29 | | | | | | | 1,540(f) | | | | | 25,087 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1,475(d) | | | | | 1,475 | | | | | — | | | | | 99.66 | | | | | 01/23/30 | | | | | | | 2,579(d) | | | | | 42,012 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 1,375(e) | | | | | 4,125 | | | | | — | | | | | 29.46 | | | | | 01/22/31 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 4,400(f) | | | | | 13,200 | | | | | — | | | | | 14.44 | | | | | 01/27/32 | | | | | | | 7,725(c) | | | | | 95,558 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 34,875(h) | | | | | 58,125 | | | | | — | | | | | 21.38 | | | | | 06/14/31 | | | | | | | 41,949(e) | | | | | 518,909 | | | | | 5,150(c) | | | | | 63,706 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 4,400(f) | | | | | 13,200 | | | | | — | | | | | 14.44 | | | | | 01/27/32 | | | | | | | 7,725(c) | | | | | 95,558 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Linda Richardson | | | | 12,280(i) | | | | | — | | | | | — | | | | | 102.20 | | | | | 08/15/28 | | | | | | | 909(a) | | | | | 11,244 | | | | | 4,600(d) | | | | | 56,902 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | 5,000(c) | | | | | — | | | | | — | | | | | 110.80 | | | | | 01/16/29 | | | | | | | 2,985(b) | | | | | 36,924 | | | | | 5,150(c) | | | | | 63,706 | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4,422(d) | | | | | 1,474 | | | | | — | | | | | 99.66 | | | | | 01/23/30 | | | | | | | 4,149(f) | | | | | 51,323 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4,750(e) | | | | | 4,750 | | | | | — | | | | | 29.46 | | | | | 01/22/31 | | | | | | | 7.725(c) | | | | | 95,558 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 3,895(j) | | | | | 4,605 | | | | | — | | | | | 31.32 | | | | | 02/15/31 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4,400(f) | | | | | 13,200 | | | | | — | | | | | 14.44 | | | | | 01/27/32 | | | | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jared Freedberg | | | | —(i) | | | | | 69,400 | | | | | — | | | | | 36.90 | | | | | 02/01/31 | | | | | | | 44,277(g) | | | | | 721,272 | | | | | — | | | | | — | | | | | | 31,808(k) | | | | | 37,592 | | | | | — | | | | | 36.90 | | | | | 02/01/31 | | | | | | | 24,906(g) | | | | | 308,087 | | | | | 5,150(c) | | | | | 63,706 | | | ||||||||||||||||
Michelle Berrey | | | | —(j) | | | | | 93,000 | | | | | — | | | | | 21.38 | | | | | 06/14/31 | | | | | | | 67,118(h) | | | | | 1,093,352 | | | | | — | | | | | — | | | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Gail Cawkwell | | | | | 19,823(k) | | | | | 956 | | | | | — | | | | | 54.63 | | | | | 02/12/28 | | | | | | | 940(i) | | | | | 15,313 | | | | | 1,650(a) | | | | | 26,879 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 5,025(c) | | | | | 1,675 | | | | | — | | | | | 110.80 | | | | | 01/16/29 | | | | | | | 1,025(a) | | | | | 16,697 | | | | | 1,700(b) | | | | | 27,693 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 3,450(d) | | | | | 3,450 | | | | | — | | | | | 99.66 | | | | | 01/23/30 | | | | | | | 2,100(b) | | | | | 34,209 | | | | | 5,050(c) | | | | | 82,265 | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | 4,925(e) | | | | | 14,775 | | | | | — | | | | | 29.46 | | | | | 01/22/31 | | | | | | | 9,450(c) | | | | | 153,941 | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Jared Freedberg | | | | | 4,400(f) | | | | | 13,200 | | | | | — | | | | | 14.44 | | | | | 01/27/32 | | | | | | | 7,725(c) | | | | | 95,558 | | | | | — | | | | | — | | |
Option | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | | | | | 02/23/17 | | | | | | — | | |
(b) | | | | | 02/05/18 | | | | | | 01/01/18 | | |
(c) | | | | | 01/16/19 | | | | | | 01/01/19 | | |
(d) | | | | | 01/23/20 | | | | | | 01/01/20 | | |
(e) | | | | | 01/22/21 | | | | | | 01/01/21 | | |
(f) | | | | | 01/27/22 | | | | | | 01/01/22 | | |
(g) | | | | | 06/21/21 | | | | | | 06/21/21 | | |
(h) | |||||||||||||
| | | | 06/14/21 | | | | | | 06/14/21 | | | |
| | | | | | | | | 08/15/18 | | | ||
(j) | | | | | 02/ | | | | | | 02/15/21 | | |
(k) | | | | | 02/01/21 | | | | | | 02/01/21 | | |
Shares or Units | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | |||||||||||||
| | | | 01/23/20 | | | | | | 01/01/20 | | | |
| | | | 01/22/21 | | | | | | 01/01/21 | | | |
| | | | 01/27/22 | | | | | | 01/01/22 | | | |
(d) | | | | | 06/21/21 | | | | | | 06/21/21 | | |
| | | | | | | | | | | |||
(f) | | | | | 02/15/21 | | | | | | 02/15/21 | | |
(g) | | | | | 02/01/21 | | | | | | 02/01/21 | | |
Shares or Units | | | Grant Date | | | Vesting Commencement Date | | ||||||
(a) | |||||||||||||
| | | | 01/23/20 | | | | | | 01/01/20 | | | |
| | | | 01/22/21 | | | | | | 01/01/21 | | | |
(c) | | | | | 01/27/22 | | | | | | 01/01/22 | | |
(d) | | | | | 02/15/21 | | | | | | 01/01/21 | | |
| | Option Awards | | Stock Awards | | | Option Awards | | Stock Awards | | ||||||||||||||||||||||||||||||||||||||||
Name | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise ($) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(1) | | | Number of Shares Acquired on Exercise (#) | | Value Realized on Exercise ($) | | Number of Shares Acquired on Vesting (#) | | Value Realized on Vesting ($)(1) | | ||||||||||||||||||||||||||||||||
Jerome Durso | | | | — | | | | | — | | | | | 20,837 | | | | | 367,103 | | | | | | — | | | | | — | | | | | 26,275 | | | | | 328,354 | | | ||||||||
Andrew Saik | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | 22,133 | | | | | 286,757 | | | ||||||||
Sandip Kapadia | | | | — | | | | | — | | | | | 869 | | | | | 21,464 | | | |||||||||||||||||||||||||||||
Rocco Venezia | | | | — | | | | | — | | | | | 3,441 | | | | | 56,157 | | | |||||||||||||||||||||||||||||
Michelle Berrey | | | | — | | | | | — | | | | | 27,744 | | | | | 369,454 | | | |||||||||||||||||||||||||||||
Linda Richardson | | | | — | | | | | — | | | | | 10,598 | | | | | 153,344 | | | |||||||||||||||||||||||||||||
Jared Freedberg | | | | — | | | | | — | | | | | — | | | | | — | | | | | | — | | | | | — | | | | | 21,946 | | | | | 339,825 | | | ||||||||
Michelle Berrey | | | | — | | | | | — | | | | | — | | | | | — | | | |||||||||||||||||||||||||||||
Gail Cawkwell | | | | — | | | | | — | | | | | 8,981 | | | | | 163,418 | | |
| | | Termination Due to Death or Disability ($) | | | Termination Without Cause or Resignation for Good Reason ($) | | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($) | | |||||||||
Jerome Durso | | | | | | | | | | | | | | | | | | | |
Cash Payments(1) | | | | | 483,525 | | | | | | 1,174,275 | | | | | | 2,348,550 | | |
Value of Accelerated Vesting(2) | | | | | 1,220,121 | | | | | | 790,065 | | | | | | 1,875,748 | | |
Health Insurance Benefits(3) | | | | | — | | | | | | 36,635 | | | | | | 73,270 | | |
Total | | | | | 1,703,646 | | | | | | 2,000,975 | | | | | | 4,297,568 | | |
Andrew Saik | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | 475,000 | | | | | | 475,000 | | |
Value of Accelerated Vesting | | | | | — | | | | | | 360,547 | | | | | | 849,621 | | |
Health Insurance Benefits | | | | | — | | | | | | 36,635 | | | | | | 36,635 | | |
Total | | | | | — | | | | | | 872,182 | | | | | | 1,361,256 | | |
Rocco Venezia | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | — | | | | | | — | | |
Value of Accelerated Vesting | | | | | — | | | | | | 64,460 | | | | | | 86,565 | | |
Health Insurance Benefits | | | | | — | | | | | | — | | | | | | — | | |
Total | | | | | — | | | | | | 64,460 | | | | | | 86,565 | | |
Jared Freedberg | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | 461,600 | | | | | | 461,600 | | |
Value of Accelerated Vesting | | | | | — | | | | | | 357,500 | | | | | | 721,272 | | |
Health Insurance Benefits | | | | | — | | | | | | 36,635 | | | | | | 36,635 | | |
Total | | | | | — | | | | | | 855,736 | | | | | | 1,219,508 | | |
Michelle Berrey | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | 600,000 | | | | | | 600,000 | | |
Value of Accelerated Vesting | | | | | — | | | | | | 451,950 | | | | | | 1,093,352 | | |
Health Insurance Benefits | | | | | — | | | | | | 32,682 | | | | | | 32,682 | | |
Total | | | | | — | | | | | | 1,084,631 | | | | | | 1,726,034 | | |
| | | Termination Due to Death or Disability ($) | | | Termination Without Cause or Resignation for Good Reason ($) | | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($) | | |||||||||
Gail Cawkwell | | | | | | | | | | | | | | | | | | | |
Cash Payments | | | | | — | | | | | | 719,925 | | | | | | 719,925 | | |
Value of Accelerated Vesting | | | | | 218,286 | | | | | | 111,994 | | | | | | 327,778 | | |
Health Insurance Benefits | | | | | — | | | | | | 36,635 | | | | | | 36,635 | | |
Total | | | | | 218,286 | | | | | | 868,554 | | | | | | 1,084,338 | | |
|
| | | | | | Termination Due to Death or Disability ($) | | | Termination Without Cause or Resignation for Good Reason ($) | | | Termination Without Cause or Resignation for Good Reason in Connection with a Change in Control ($) | |
Jerome Durso | | | | | | | | | | | | | |
| | | Cash Payments(1) | | | 501,900 | | | 1,218,900 | | | 2,437,800 | |
| | | Value of Accelerated Vesting(2) | | | 2,183,924 | | | 849,819 | | | 1,999,301 | |
| | | Health Insurance Benefits(3) | | | — | | | 39,361 | | | 78,721 | |
| | | Total | | | 2,685,824 | | | 2,108,080 | | | 4,515,822 | |
Andrew Saik | | | | | | | | | | | | | |
| | | Cash Payments | | | — | | | 493,000 | | | 493,000 | |
| | | Value of Accelerated Vesting | | | 124,192 | | | 238,605 | | | 541,266 | |
| | | Health Insurance Benefits | | | — | | | 39,361 | | | 39,361 | |
| | | Total | | | 124,192 | | | 770,966 | | | 1,073,627 | |
Michelle Berrey | | | | | | | | | | | | | |
| | | Cash Payments | | | — | | | 622,500 | | | 622,500 | |
| | | Value of Accelerated Vesting | | | 141,541 | | | 284,869 | | | 656,938 | |
| | | Health Insurance Benefits | | | — | | | 24,960 | | | 24,960 | |
| | | Total | | | 141,541 | | | 932,329 | | | 1,304,398 | |
Linda Richardson | | | | | | | | | | | | | |
| | | Cash Payments | | | — | | | 498,000 | | | 498,000 | |
| | | Value of Accelerated Vesting | | | 190,340 | | | 116,389 | | | 313,390 | |
| | | Health Insurance Benefits | | | — | | | 11,871 | | | 11,871 | |
| | | Total | | | 190,340 | | | 626,260 | | | 823,261 | |
Jared Freedberg | | | | | | | | | | | | | |
| | | Cash Payments | | | — | | | 479,000 | | | 479,000 | |
| | | Value of Accelerated Vesting | | | 115,050 | | | 206,505 | | | 446,116 | |
| | | Health Insurance Benefits | | | — | | | 39,361 | | | 39,361 | |
| | | Total | | | 115,050 | | | 724,866 | | | 964,477 | |
Plan Category | | | Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants, and Rights | | | Weighted-Average Exercise Price of Outstanding Options, Warrants, and Rights | | | Number of Securities Remaining Available for Future Issuance | | |||||||||
Equity Compensation Plans Approved by Security Holders(1) | | | | | | | | | $ | | | | | | | | |||
Equity Compensation Plans Not Approved by Security Holders | | | | | — | | | | | | — | | | | | | — | | |
Year | | | Summary compensation table total for PEO (Mark Pruzanski)(1) ($) | | | Summary compensation table total for PEO (Jerome Durso)(1) ($) | | | Compensation actually paid to PEO (Mark Pruzanski)(1)(2)(3) ($) | | | Compensation actually paid to PEO (Jerome Durso)(1)(2)(3) ($) | | | Average summary compensation table total for Non-PEO NEOs(1) ($) | | | Average compensation actually paid to Non-PEO NEOs(1)(2)(3) ($) | | | Value of initial fixed $100 investment based on:(4) | | | Net Income ($ thousands) | | | Relative TSR Percentile Rank(5) | | ||||||||||||||||||||||||||||||
| TSR ($) | | | Peer Group TSR ($) | | |||||||||||||||||||||||||||||||||||||||||||||||||||||
(a) | | | (b) | | | (b) | | | (c) | | | (c) | | | (d) | | | (e) | | | (f) | | | (g) | | | (h) | | | (i) | | |||||||||||||||||||||||||||
2022 | | | | | — | | | | | | 4,455,463 | | | | | | — | | | | | | 3,021,702 | | | | | | 1,412,607 | | | | | | 1,057,033 | | | | | | 9.98 | | | | | | 113.65 | | | | | | 221,816 | | | | 66th percentile | |
2021 | | | | | — | | | | | | 7,870,354 | | | | | | — | | | | | | 4,188,569 | | | | | | 2,407,933 | | | | | | 1,453,145 | | | | | | 13.15 | | | | | | 126.45 | | | | | | (91,426) | | | | 33rd percentile | |
2020 | | | | | 6,427,005 | | | | | | — | | | | | | (7,011,160) | | | | | | — | | | | | | 2,483,654 | | | | | | (2,670,814) | | | | | | 19.93 | | | | | | 126.42 | | | | | | (274,880) | | | | 1st percentile | |
| 2020 | | | 2021 | | | 2022 | |
| Jerome Durso | | | Andrew Saik | | | Andrew Saik | |
| Sandip Kapadia | | | Sandip Kapadia | | | Michelle Berrey | |
| Richard Kim | | | Rocco Venezia | | | Linda Richardson | |
| Lisa Bright | | | Jared Freedberg | | | Jared Freedberg | |
| Ryan Sullivan | | | Michelle Berrey | | | | |
| Christian Weyer | | | Gail Cawkwell | | | | |
Year | | | Summary Compensation Table Total for Mark Pruzanski ($) | | | Exclusion of Stock Awards and Option Awards for Mark Pruzanski ($) | | | Inclusion of Equity Values for Mark Pruzanski ($) | | | Compensation Actually Paid to Mark Pruzanski ($) | | ||||||||||||
2020 | | | | | 6,427,005 | | | | | | (5,129,500) | | | | | | (8,308,665) | | | | | | (7,011,160) | | |
Year | | | Summary Compensation Table Total for Jerome Durso ($) | | | Exclusion of Stock Awards and Option Awards for Jerome Durso ($) | | | Inclusion of Equity Values for Jerome Durso ($) | | | Compensation Actually Paid to Jerome Durso ($) | | ||||||||||||
2022 | | | | | 4,455,463 | | | | | | (3,082,978) | | | | | | 1,649,217 | | | | | | 3,021,702 | | |
2021 | | | | | 7,870,354 | | | | | | (6,709,665) | | | | | | 3,027,880 | | | | | | 4,188,569 | | |
Year | | | Average Summary Compensation Table Total for Non-PEO NEOs ($) | | | Average Exclusion of Stock Awards and Option Awards for Non-PEO NEOs ($) | | | Average Inclusion of Equity Values for Non-PEO NEOs ($) | | | Average Compensation Actually Paid to Non-PEO NEOs ($) | | ||||||||||||
2022 | | | | | 1,412,607 | | | | | | (499,099) | | | | | | 143,525 | | | | | | 1,057,033 | | |
2021 | | | | | 2,407,933 | | | | | | (1,749,813) | | | | | | 795,025 | | | | | | 1,453,145 | | |
2020 | | | | | 2,483,654 | | | | | | (1,765,912) | | | | | | (3,388,556) | | | | | | (2,670,814) | | |
Year | | | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Mark Pruzanski ($) | | | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Mark Pruzanski ($) | | | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Mark Pruzanski ($) | | | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Mark Pruzanski ($) | | | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Mark Pruzanski ($) | | | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Mark Pruzanski ($) | | | Total — Inclusion of Equity Values for Mark Pruzanski ($) | | |||||||||||||||||||||
2020 | | | | | 1,237,142 | | | | | | (4,631,093) | | | | | | 243,359 | | | | | | (5,158,073) | | | | | | — | | | | | | — | | | | | | (8,308,665) | | |
Year | | | Year-End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Jerome Durso ($) | | | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Jerome Durso ($) | | | Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Jerome Durso ($) | | | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Jerome Durso ($) | | | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Jerome Durso ($) | | | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Jerome Durso ($) | | | Total — Inclusion of Equity Values for Jerome Durso ($) | | |||||||||||||||||||||
2022 | | | | | 2,360,592 | | | | | | (832,716) | | | | | | 221,501 | | | | | | (100,160) | | | | | | — | | | | | | — | | | | | | 1,649,217 | | |
2021 | | | | | 3,080,047 | | | | | | (282,100) | | | | | | 336,351 | | | | | | (106,418) | | | | | | — | | | | | | — | | | | | | 3,027,880 | | |
Year | | | Average Year- End Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year for Non- PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards for Non-PEO NEOs ($) | | | Average Vesting-Date Fair Value of Equity Awards Granted During Year that Vested During Year for Non-PEO NEOs ($) | | | Average Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year for Non-PEO NEOs ($) | | | Average Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year for Non-PEO NEOs ($) | | | Average Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included for Non-PEO NEOs ($) | | | Total — Average Inclusion of Equity Values for Non-PEO NEOs ($) | | |||||||||||||||||||||
2022 | | | | | 358,021 | | | | | | (207,275) | | | | | | 63,960 | | | | | | (71,181) | | | | | | — | | | | | | — | | | | | | 143,525 | | |
2021 | | | | | 887,336 | | | | | | (27,614) | | | | | | 19,577 | | | | | | (15,546) | | | | | | (68,728) | | | | | | — | | | | | | 795,025 | | |
2020 | | | | | 220,171 | | | | | | (1,490,284) | | | | | | 63,097 | | | | | | (771,846) | | | | | | (1,409,694) | | | | | | — | | | | | | (3,388,556) | | |
| | Year Ended December | | | Year Ended December 31, | | ||||||||||||||||||||
| | 31, 2021 | | 2020 | | | 2022 | | 2021 | | ||||||||||||||||
| | (in thousands) | | | (in thousands) | | ||||||||||||||||||||
Audit Fees | | | $ | 1,869 | | | | $ | 1,615 | | | | | $ | 2,167 | | | | $ | 1,869 | | | ||||
Audit-Related Fees | | | | — | | | | | — | | | | | | — | | | | | — | | | ||||
Tax Fees | | | | 134 | | | | | 124 | | | | | | 141 | | | | | 134 | | | ||||
All Other Fees | | | | 2 | | | | | 2 | | | | | | — | | | | | 2 | | | ||||
Total Fees | | | $ | 2,005 | | | | $ | 1,741 | | | | | $ | 2,308 | | | | $ | 2,005 | | |